{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:11:13Z","timestamp":1737436273670,"version":"3.33.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/bf02686085","type":"journal-article","created":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T14:17:41Z","timestamp":1187273861000},"page":"85-95","source":"Crossref","is-referenced-by-count":4,"title":["Indications for biotherapy in systemic vasculitides"],"prefix":"10.1007","volume":"32","author":[{"given":"Lo\u00efc","family":"Guillevin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Guilpain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02686085_CR1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0755-4982(04)98936-1","volume":"33","author":"P. Cohen","year":"2004","unstructured":"Cohen P. and Guillevin, L. (2004), Vasculitis associated with viral infections [French]. Presse M\u00e9d 33, 1371\u20131384.","journal-title":"Presse M\u00e9d"},{"key":"BF02686085_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","volume":"84","author":"L. Guillevin","year":"2005","unstructured":"Guillevin L., Mahr, A., Callard, P., et al. (2005), Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84, 313\u2013322.","journal-title":"Medicine (Baltimore)"},{"key":"BF02686085_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"J.C. Jennette","year":"1994","unstructured":"Jennette, J.C., Falk, R.J., Andrassy, K., et al. (1994), Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37, 187\u2013192.","journal-title":"Arthritis Rheum"},{"key":"BF02686085_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/art.1780330805","volume":"33","author":"R.W. Lightfoot Jr.","year":"1990","unstructured":"Lightfoot, R.W., Jr., Michel, B.A. Bloch, D.A. et al. (1990). The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33, 1088\u20131093.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"BF02686085_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.amjmed.2004.03.024","volume":"117","author":"B.L. Pearlman","year":"2004","unstructured":"Pearlman, B.L. (2004), Hepatitis C treatment update. Am J Med 117, 5, 344\u2013352.","journal-title":"Am J Med"},{"key":"BF02686085_CR6","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S. Zeuzem","year":"2000","unstructured":"Zeuzem, S., Feinman, S.V., Rasenack, J., et al. (2000), Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343, 1666\u20131672.","journal-title":"N Engl J Med"},{"key":"BF02686085_CR7","first-page":"81","volume":"147","author":"P. Cohen","year":"1996","unstructured":"Cohen, P., Nguyen, Q.T., D\u00e9ny, P., et al. (1996), Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Ann M\u00e9d Interne (Paris) 147, 81\u201386.","journal-title":"Ann M\u00e9d Interne (Paris)"},{"key":"BF02686085_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1196\/annals.1361.121","volume":"1051","author":"Y. Levy","year":"2005","unstructured":"Levy, Y., Uziel, Y., Zandman, G. et al. (2005), Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 1051, 779\u2013786.","journal-title":"Ann N Y Acad Sci"},{"key":"BF02686085_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.20958","volume":"52","author":"P. Cacoub","year":"2005","unstructured":"Cacoub, P., Saadoun, D., Limal, N., Sene, D., Lidove, O., and Piette, J.C. (2005), PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52, 911\u2013915.","journal-title":"Arthritis Rheum"},{"key":"BF02686085_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1526-0968.2003.00036.x","volume":"7","author":"L. Guillevin","year":"2003","unstructured":"Guillevin, L. and Pagnoux, C. (2003), Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 7, 155\u2013160.","journal-title":"Ther Apher Dial"},{"key":"BF02686085_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1136\/ard.2002.004929","volume":"62","author":"P. Lamprecht","year":"2003","unstructured":"Lamprecht, P., Lerin-Lozano, C., Merz, H. et al. (2003), Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62, 1230\u20131233.","journal-title":"Ann Rheum Dis"},{"key":"BF02686085_CR12","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F. Zaja","year":"2003","unstructured":"Zaja, F., De Vita, S., Mazzero, C., et al. (2003), Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101, 3827\u20133834.","journal-title":"Blood"},{"key":"BF02686085_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"D.R. Jayne","year":"2002","unstructured":"Jayne, D.R., Chapel, H., Adu, D., et al. (2002), Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93, 433\u2013439.","journal-title":"QJM"},{"key":"BF02686085_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","volume":"337","author":"D.R. Jayne","year":"1991","unstructured":"Jayne, D.R., Davies, M.J., Fox, C.J., Black, C.M., and Lockwood, C.M. (1991), Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337, 1137\u20131139.","journal-title":"Lancet"},{"key":"BF02686085_CR15","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","volume":"35","author":"D.R. Jayne","year":"1996","unstructured":"Jayne, D.R. and Lockwood, C.M. (1996), Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35, 1150\u20131153.","journal-title":"Br J Rheumatol"},{"key":"BF02686085_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/ard.2002.003996","volume":"62","author":"Y. Levy","year":"2003","unstructured":"Levy, Y., Uziel, Y., Zandman, G.G., et al. (2003), Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 62, 1221\u20131223.","journal-title":"Ann Rheum Dis"},{"key":"BF02686085_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","volume":"101","author":"C. Richter","year":"1995","unstructured":"Richter, C., Schnabel, A., Csernok, E., De Groot, K., Reinhold-Keller, E., and Gross, W.L. (1995), Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101, 2\u20137.","journal-title":"Clin Exp Immunol"},{"key":"BF02686085_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/art.21101","volume":"52","author":"V. Martinez","year":"2005","unstructured":"Martinez, V., Cohen, P., Mouthon, L., and Guillevin, L.FVSG. (2005), Intravenous immunoglobulins for relapses of ANCA-associated systemic vasculitides: final analysis of a prospective, open and multicenter trial. Arthritis Rheum 52, 649.","journal-title":"Arthritis Rheum"},{"key":"BF02686085_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000056085","volume":"62","author":"Y. Sherer","year":"2001","unstructured":"Sherer, Y., Levy, Y., Langevitz, P., Rauova, L., Fabrizzi, F., and Shoenfeld, Y. (2001), Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 62, 133\u2013137.","journal-title":"Pharmacology"},{"key":"BF02686085_CR20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0755-4982(04)98888-4","volume":"33","author":"P. Guilpain","year":"2004","unstructured":"Guilpain, P., Chanseaud, Y., Tamby, M.C., et al. (2004), Immunomodulatory effects of intravenous immunoglobulins [in French]. Presse M\u00e9d 33, 1183\u20131194.","journal-title":"Presse M\u00e9d"},{"key":"BF02686085_CR21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","volume":"336","author":"D.R. Jayne","year":"1993","unstructured":"Jayne, D.R. and Lockwood, C.M. (1993). Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336, 469\u2013472.","journal-title":"Adv Exp Med Biol"},{"key":"BF02686085_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","volume":"15","author":"A. Booth","year":"2004","unstructured":"Booth, A., Harper, L., Hammad, T., et al. (2004), Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15, 717\u2013721.","journal-title":"J Am Soc Nephrol"},{"key":"BF02686085_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","volume":"41","author":"P. Bartolucci","year":"2002","unstructured":"Bartolucci, P., Ramanoelina, J., Cohen, P., et al. (2002), Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41, 1126\u20131132.","journal-title":"Rheumatology (Oxford)"},{"key":"BF02686085_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"WGET","year":"2005","unstructured":"WGET. (2005), Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 352, 351\u2013361.","journal-title":"N Engl J Med"},{"key":"BF02686085_CR25","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.21869","volume":"54","author":"J.H. Stone","year":"2006","unstructured":"Stone, J.H., Holbrook, J.T., Marriott, M.A., et al. (2006), Solid malignancies among patients in the Wegener\u2019s granulomatosis etanercept trial. Arthritis Rheum 54, 1608\u20131618.","journal-title":"Arthritis Rheum"},{"key":"BF02686085_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"K.A. Keogh","year":"2006","unstructured":"Keogh, K.A., Ytterberg, S.R., Fervenza, F.C., Carlson, K.A., Schroeder, D.R., and Specks, U. (2006), Rituximab for refractory Wegener\u2019s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173, 180\u2013187.","journal-title":"Am J Respir Crit Care Med"},{"key":"BF02686085_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","volume":"257","author":"P. Eriksson","year":"2005","unstructured":"Eriksson, P. (2005), Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257, 540\u2013548.","journal-title":"J Intern Med"},{"key":"BF02686085_CR28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1523-1755.2004.00534.x","volume":"65","author":"W.H. Schmitt","year":"2004","unstructured":"Schmitt, W.H., Hagen, E.C., Neumann, I., Nowack, R., Flores-Suarez, L.F., and van der Woude, F.J. (2004), Treatment of refractory Wegener\u2019s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65, 1440\u20131448.","journal-title":"Kidney Int"},{"key":"BF02686085_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1046\/j.1365-2249.2001.01575.x","volume":"126","author":"K. Steiner","year":"2001","unstructured":"Steiner, K., Moosig, F., Csernok, E., et al. (2001), Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener\u2019s granulomatosis. Clin Exp Immunol 126, 143\u2013150.","journal-title":"Clin Exp Immunol"},{"key":"BF02686085_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jaut.2005.08.004","volume":"25","author":"M. Krumbholz","year":"2005","unstructured":"Krumbholz, M., Specks, U., Wick, M., Kalled, S.L., Jenne, D., and Meinl, E. (2005), Is elevated in serum of patients with Wegener\u2019s granulomatosis. J Autoimmun 25, 298\u2013302.","journal-title":"J Autoimmun"},{"key":"BF02686085_CR31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","volume":"143","author":"R. Sabl\u00e9-Fourtassou","year":"2005","unstructured":"Sabl\u00e9-Fourtassou, R., Cohen, P., Mahr, A., et al. (2005), Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143, 632\u2013638.","journal-title":"Ann Intern Med"},{"key":"BF02686085_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/1529-0131(200008)43:8<1897::AID-ANR29>3.0.CO;2-I","volume":"43","author":"E. Peen","year":"2000","unstructured":"Peen, E., Hahn, P., Lauwers, G., Williams, R.C., Jr., Gleich, G., and Kephart, G.M. (2000), Churg-Strauss syndrome: localization of eosinophil major basic protein in damaged tissues. Arthritis Rheum 43, 1897\u20131900.","journal-title":"Arthritis Rheum"},{"key":"BF02686085_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2500\/108854199778681486","volume":"20","author":"A. Tsukadaira","year":"1999","unstructured":"Tsukadaira, A., Okubo, Y., Kitano, K., et al. (1999), Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc 20, 39\u201344.","journal-title":"Allergy Asthma Proc"},{"key":"BF02686085_CR34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archderm.137.11.1527","volume":"137","author":"C.C. Termeer","year":"2001","unstructured":"Termeer, C.C., Simon, J.C., and Schopf, E. (2001), Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 137, 136\u2013138.","journal-title":"Arch Dermatol"},{"key":"BF02686085_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1074-7613(00)80122-3","volume":"11","author":"D.H. Zhang","year":"1999","unstructured":"Zhang, D.H., Yang, L., Cohn, L., et al. (1999), Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 11, 473\u2013482.","journal-title":"Immunity"},{"key":"BF02686085_CR36","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0022-3565(24)35210-3","volume":"291","author":"P. Zia-Amirhosseini","year":"1999","unstructured":"Zia-Amirhosseini, P., Minthorn, E., Benincosa, L.J., et al. (1999), Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291, 1060\u20131067.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02686085_CR37","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","volume":"103","author":"A.D. Klion","year":"2004","unstructured":"Klion, A.D., Law, M.A., Noel, P., Kim, Y.J., Haverty, T.P., and Nutman, T.B. (2004), Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103, 2939\u20132941.","journal-title":"Blood"},{"key":"BF02686085_CR38","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"J.C. Kips","year":"2003","unstructured":"Kips, J.C., O\u2019Connor, B.J., Langley, S.J., et al. (2003), Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167, 1655\u20131659.","journal-title":"Am J Respir Crit Care Med"},{"key":"BF02686085_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1172\/JCI200317974","volume":"112","author":"P. Flood-Page","year":"2003","unstructured":"Flood-Page, P., Menzies-Gow, A., Phipps, S., et al. (2003), Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112, 1029\u20131036.","journal-title":"J Clin Invest"},{"key":"BF02686085_CR40","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"M.J. Leckie","year":"2000","unstructured":"Leckie, M.J., ten Brinke, A., Khan, J., et al. (2000), Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144\u20132148.","journal-title":"Lancet"},{"key":"BF02686085_CR41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","volume":"129","author":"E. Tatsis","year":"1998","unstructured":"Tatsis, E., Schnabel, A., and Gross, W.L. (1998), Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129, 370\u2013374.","journal-title":"Ann Intern Med"},{"key":"BF02686085_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-3083.1985.tb01443.x","volume":"21","author":"B.J. Manger","year":"1985","unstructured":"Manger, B.J., Krapf, F.E., Gramatzki, M., et al. (1985), IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Immunol 21, 369\u2013373.","journal-title":"Scand J Immunol"},{"key":"BF02686085_CR43","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaci.2005.05.035","volume":"116","author":"Y.E. Ong","year":"2005","unstructured":"Ong, Y.E., Menzies-Gow, A., Barkans, J., et al. (2005), Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116, 558\u2013564.","journal-title":"J Allergy Clin Immunol"},{"key":"BF02686085_CR44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","volume":"164","author":"W.W. Busse","year":"2001","unstructured":"Busse, W.W. (2001), Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 164, 12\u201317.","journal-title":"Am J Respir Crit Care Med"},{"key":"BF02686085_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejphar.2005.12.045","volume":"533","author":"G. D\u2019Amato","year":"2006","unstructured":"D\u2019Amato, G. (2006), Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol 533, 302\u2013307.","journal-title":"Eur J Pharmacol"},{"key":"BF02686085_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000055677","volume":"33","author":"M. Santos Lacomba","year":"2001","unstructured":"Santos Lacomba, M., Marcos Martin, C., Gallardo Galera, J.M., et al. (2001), Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33, 251\u2013255.","journal-title":"Ophthalmic Res"},{"key":"BF02686085_CR47","doi-asserted-by":"publisher","first-page":"295,296","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"P.P. Sfikakis","year":"2001","unstructured":"Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., Kaklamanis, P., Markomichelakis, N.N. (2001), Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet 358, 295,296.","journal-title":"Lancet"},{"key":"BF02686085_CR48","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","volume":"110","author":"A. Joseph","year":"2003","unstructured":"Joseph, A., Raj, D., Dua, H.S., Powell, P.T., Lanyon, P.C., and Powell, R.J. (2003), Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110, 1449\u20131453.","journal-title":"Ophthalmology"},{"key":"BF02686085_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","volume":"111","author":"C.C. Murphy","year":"2004","unstructured":"Murphy, C.C., Ayliffe, W.H., Booth, A., Makanjuola, D., Andrews, P.A., and Jayne, D. (2004), Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111, 352\u2013356.","journal-title":"Ophthalmology"},{"key":"BF02686085_CR50","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","volume":"34","author":"N. Lanthier","year":"2005","unstructured":"Lanthier, N., Parc, C., Scavennec, R., Dhote, R., Br\u00e9zin, A., and Guillevin, L. (2005), Infliximab in the treatment of posterior uveitis in Behcet\u2019s disease. Long term follow up in four patients. Presse M\u00e9d 34, 916\u2013918.","journal-title":"Presse M\u00e9d"},{"key":"BF02686085_CR51","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/art.1780400615","volume":"40","author":"P.B. Martens","year":"1997","unstructured":"Martens, P.B., Goronzy, J.J., Schaid, D., and Weyand, C.M. (1997), Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 40, 1106\u20131114.","journal-title":"Arthritis Rheum"},{"key":"BF02686085_CR52","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/rheumatology\/keg230","volume":"42","author":"J. Zou","year":"2003","unstructured":"Zou, J., Zhang, Y., Thiel, A., et al. (2003), Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 42, 846\u2013855.","journal-title":"Rheumatology (Oxford)"},{"key":"BF02686085_CR53","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/rheumatology\/40.12.1346","volume":"40","author":"C. Turesson","year":"2001","unstructured":"Turesson, C., Englund, P., Jacobsson, L.T., et al. (2001), Increased endothelial expression of HLA-DQ and interleukin 1alpha in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle. Rheumatology (Oxford) 40, 1346\u20131354.","journal-title":"Rheumatology (Oxford)"},{"key":"BF02686085_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/qjmed\/90.2.125","volume":"90","author":"L. Harper","year":"1997","unstructured":"Harper, L., Cockwell, P., Howie, A.J., et al. (1997), Focal segmental necrotizing glomerulonephritis in rheumatoid arthritis. QJM 90, 125\u2013132.","journal-title":"QJM"},{"issue":"3","key":"BF02686085_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0002-9343(84)90654-5","volume":"76","author":"D.G. Scott","year":"1984","unstructured":"Scott, D.G. and Bacon, P.A. (1984), Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76 3, 377\u2013384.","journal-title":"Am J Med"},{"key":"BF02686085_CR56","doi-asserted-by":"publisher","first-page":"538,539","DOI":"10.1136\/ard.60.5.538","volume":"60","author":"A.A. den Broeder","year":"2001","unstructured":"den Broeder, A.A., van den Hoogen, F.H., and van de Putte, L.B. (2001), Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. Ann Rheum Dis 60, 538,539.","journal-title":"Ann Rheum Dis"},{"key":"BF02686085_CR57","first-page":"234,235","volume":"41","author":"C. Garcia-Porrua","year":"2002","unstructured":"Garcia-Porrua, C. and Gonzalez-Gay, M.A. (2002), Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Rheumatology (Oxford) 41, 234,235.","journal-title":"Rheumatology (Oxford)"},{"key":"BF02686085_CR58","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/rheumatology\/39.12.1436","volume":"39","author":"C. Richter","year":"2000","unstructured":"Richter, C., Wanke, L., Steinmetz, J., Reinhold-Keller, E., and Gross, W.L. (2000), Mononeuritis secondary to rheumatoid arthritis responds to etanercept. Rheumatology (Oxford) 39, 1436\u20131437.","journal-title":"Rheumatology (Oxford)"},{"key":"BF02686085_CR59","doi-asserted-by":"publisher","first-page":"587,588","DOI":"10.1136\/ard.62.6.587","volume":"62","author":"L. Unger","year":"2003","unstructured":"Unger, L., Kayser, M., and Nusslein, H.G. (2003), Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 62, 587,588.","journal-title":"Ann Rheum Dis"},{"key":"BF02686085_CR60","first-page":"1607","volume":"32","author":"A.E. van der Bijl","year":"2005","unstructured":"van der Bijl, A.E., Allaart, C.F., Van Vugt, J., Van Duinen, S., and Breedveld, F.C. (2005), Rheumatoid vasculitis treated with infliximal. J Rheumatol 32, 1607\u20131609.","journal-title":"J Rheumatol"},{"key":"BF02686085_CR61","first-page":"2079","volume":"31","author":"P. Richette","year":"2004","unstructured":"Richette, P., Dieude, P., Damiano, J., Liote, F., Orcel, P., and Bardin, T. (2004), Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 31, 2079\u20132081.","journal-title":"J Rheumatol"},{"key":"BF02686085_CR62","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"A.K. Mohan","year":"2004","unstructured":"Mohan, A.K., Cote, T.R., Block, J.A., Manadan, A.M., Siegel, J.N., and Braun, M.M. (2004), Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39, 295\u2013299.","journal-title":"Clin Infect Dis"},{"key":"BF02686085_CR63","first-page":"1885","volume":"31","author":"L. Guillevin","year":"2004","unstructured":"Guillevin, L. and Mouthon, L. (2004), Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 31, 1885\u20131857.","journal-title":"J Rheumatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02686085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02686085\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02686085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02686085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:51:14Z","timestamp":1737373874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02686085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["BF02686085"],"URL":"https:\/\/doi.org\/10.1007\/bf02686085","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"type":"print","value":"1080-0549"},{"type":"electronic","value":"1559-0267"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}